Innovation Focus Pathios Therapeutics specializes in cutting-edge GPCR drug development with a strong emphasis on immunology, particularly GPR65, enabling potential collaborations in novel immunotherapy platforms and targeted cancer treatments.

Funding Momentum With a recent Series B financing of $25 million and significant Series A funding of $33 million from top-tier investors, the company demonstrates strong investor confidence, suggesting an active growth trajectory and opportunities for strategic partnerships.

Research Expertise The company's unique genetic and transcriptomic insights present opportunities to develop and deploy advanced analytics, lab automation, and companion diagnostic solutions to accelerate drug discovery and clinical trials.

Strategic Collaborations Supported by major industry players like Bristol Myers Squibb and integrated within the M:M Bio ecosystem, Pathios is well-positioned for joint ventures, licensing negotiations, and technology transfer collaborations in immuno-oncology and neuroinflammatory research.

Growth Potential As a clinical-stage biotech with a small but dedicated team and a revenue range of $1 million to $10 million, Pathios offers high-growth partnership opportunities with CROs, biotech service providers, and investors keen on early-stage innovative therapies.